Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$49.84 - $70.47 $6.15 Million - $8.7 Million
-123,400 Reduced 44.95%
151,100 $9.58 Million
Q2 2024

Aug 13, 2024

BUY
$47.39 - $80.2 $11.6 Million - $19.7 Million
245,100 Added 833.67%
274,500 $14.5 Million
Q1 2024

May 14, 2024

BUY
$17.4 - $94.5 $511,559 - $2.78 Million
29,400 New
29,400 $2.42 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.